University of Cambridge > Talks.cam > Cancer Research UK Cambridge Centre Lectures in Cancer Biology and Medicine > The challenges in therapeutic targeting of the RAF-MEK-ERK signalling pathway

  Browse A-Z

Log in

Googledetails Microsoftdetails

🔐 Log In

Information on

Subscribing to talksdetails Finding a talkdetails Adding a talkdetails Disseminating talksdetails Help and Documentationdetails

ℹī¸ Information

The challenges in therapeutic targeting of the RAF-MEK-ERK signalling pathway

Download to your calendar using vCal

If you have a question about this talk, please contact Louisa Bellis .

The ERK1 /2 signalling pathway is de-regulated in a variety of cancers due to mutations in RAS (especially KRAS ), BRAF and MEK . This has led to the development of a variety of protein kinase inhibitors that target BRAF , MEK or ERK . Indeed, BRAF and MEK inhibitors are now approved for treatment of melanomas harbouring BRAFV600E /K mutations. This talk will highlight some of the challenges that these kinase inhibitors face – especially intrinsic and acquired resistance – as well as some solutions.

This talk is part of the Cancer Research UK Cambridge Centre Lectures in Cancer Biology and Medicine series.

This talk is included in these lists:

Note that ex-directory lists are not shown.

Other lists

MR 12, Centre for Mathematical Sciences Webinar & FW11, Computer Laboratory, William Gates Building. Venue TBC in Cambridge

Other talks

TOWARD AFFORDABLE PREVENTIVE HEALTHCARE: How basic science addresses grand challenges How Far Can Good Go Without God? The Limits of a Naturalistic Ethic Cambridge RNA Club - ONLINE Tea and Coffee Break Psychiatry and Pain Medicine Title to be confirmed
 

Š 2006-2025 Talks.cam, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity